873551-53-2

Usage

Uses

Used in Pharmaceutical Industry:
FTIDC is used as a mGluR1 antagonist for its potential therapeutic effects in various neurological and psychiatric disorders. Its high potency and selectivity make it a promising candidate for the development of new treatments.
Used in Neurological Disorders:
FTIDC is used as a therapeutic agent for the treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its ability to modulate glutamate signaling may help alleviate symptoms and slow disease progression.
Used in Psychiatric Disorders:
FTIDC is used as a potential treatment for psychiatric disorders such as schizophrenia, anxiety, and depression. Its action as an mGluR1 antagonist may help regulate glutamate neurotransmission, leading to improvements in cognitive function and mood regulation.
Used in Drug Development:
FTIDC is used as a lead compound in the development of new drugs targeting the mGluR1 receptor. Its high potency and selectivity make it a valuable tool for understanding the role of mGluR1 in various diseases and for designing more effective therapeutic agents.

Upstream product

• 74-88-4 methyl iodide 
• 873552-32-0 4-[1-(2-fuluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-3,6-dihydropyridine-1(2H)-carboxamide 

Relevant academic research and scientific papers

Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist

We describe here the discovery and the structure-activity relationship (SAR) of a series of 4-(1-Aryltriazol-4-yl)-tetrahydropyridines as novel mGluR1 antagonists. Our extensive chemical modification of lead compound 2 successfully led to fluoropyridine a

BIARYL DERIVATIVES

The present invention relates to a compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, whrein: R 1 is a linear or branched alkoxy group, a cycloalkoxy group, a linear or branched lower alkyl group, etc.; R 2 is halogen atom, a lower alkyl group, etc.; Q 1 is carbon atom or nitrogen atom; Q 2 is carbon atom which may be substituted with oxo group; the formula (III) : is a single bond or a double bond; A is a group selected from the group consisting of the substituent group ±; and R 5 is hydrogen atom, a lower alkyl group, cyano group, an alkoxy group or a trialkylsilyl group; having an mGluR1 inhibiting action and being useful as treatment and/or prevention of convulsion, acute pain, cerebral disturbance such as cerebral infarction or transient cerebral ischemia onset, anxiety, chemical dependency or Parkinson's disease.